Drug Approval | April 14, 2026
FDA fast-tracks Daiichi Sankyo & Merck lung cancer drug review
The FDA is also reviewing the application under its Real-Time Oncology Review (RTOR) program and Project Orbis
The FDA is also reviewing the application under its Real-Time Oncology Review (RTOR) program and Project Orbis
Benefits were consistent across all key subgroups, including patients previously treated with covalent BTK inhibitors
The new test offers a minimally invasive blood-based approach to tracking neurological damage, measuring neurofilament light chain
The centre offers a full spectrum of FDA-approved services, including physiotherapy, occupational therapy, speech and language therapy, and aqua therapy
The conference focuses on the latest advances in cancer diagnosis, treatment, and patient-centric care
Spread across nearly 4,500 sq. ft., the new clinic combines advanced dental technology, experienced specialists, and an Atithi-first care model
The license is valid for five years, effective from April 9, 2026
The three-day conference is expected to bring together more than 3,000 physiotherapists, clinicians, researchers, academicians, and students
The two-day conference and exhibition features discussions on policy frameworks, AI-led drug discovery, next-generation technologies, and global competitiveness
On-site medical room brings preventive care, routine consultations, and diagnostics closer to residents
Subscribe To Our Newsletter & Stay Updated
